OpenNashEarnings

Doximity (DOCS) · Health Care

Doximity Q1 FY2027 earnings: summary, key numbers & outlook

Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Doximity's clinical AI assistant Ask ranked as the top U.S.-based model on the NOHARM benchmark, while workflow active prescriber growth topped 30% year-over-year.

Doximity pushed further into AI-assisted clinical work this quarter. Its assistant Ask (formerly DoxGPT) was the top-performing U.S.-based model in the NOHARM benchmark, and AI Search queries grew over 25% quarter-over-quarter. Providers who use workflow tools such as Dialer, Scribe, Amion, PeerCheck and Ask grew more than 30% year-over-year. Management also points to early wins in innovation budgets and in pharma, where it says it offers a lower-cost option.

Management is positioning AI as the next chapter of the doctor's digital platform, a network that reaches more than 85% of U.S. physicians. The tension is competition and cost. Scribe competes against Microsoft in a crowded market, and the AI push comes with sharply higher R&D and cost of revenue. That is squeezing margins while the company tries to convert engagement into revenue.

No call transcript for this quarter, so this summary also draws on: The Motley Fool (via Webull) ↗.

Key numbers

Revenue · GAAP
$156.6 million

up 7% year-over-year

Net income · GAAP
$24.3 million

versus $53.3 million a year ago

Diluted EPS · GAAP
$0.13

versus $0.27 a year ago

Non-GAAP diluted EPS · non-GAAP
$0.29

versus $0.36 a year ago

GAAP gross margin · GAAP
84.9%

versus 89.2% a year ago

Income from operations · GAAP
33.6M

versus 54,517 a year ago

Operating cash flow
$42.0 million

a decrease of 32% year-over-year

Free cash flow · non-GAAP
$39.6 million

a decrease of 34% year-over-year

Segment or metricValueChange
Workflow active prescriber growthmore than 30%year-over-year
AI Search query growthover 25%quarter-over-quarter
Share of U.S. physicians in networkmore than 85%
Where each number comes from
  • Revenue: “Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.”
  • Net income: “Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%.”
  • Diluted EPS: “Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.”
  • Non-GAAP diluted EPS: “Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.”
  • GAAP gross margin: “GAAP gross margin | 84.9% | 89.2% Non-GAAP gross margin | 87.5% | 91.2%”
  • Income from operations: “Total operating expenses | 99,282 | 75,603 Income from operations | 33,644 | 54,517 Other income, net | 6,719 | 9,630”
  • Operating cash flow: “Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million”
  • Free cash flow: “Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million”
  • Workflow active prescriber growth: “workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter”
  • AI Search query growth: “workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter”
  • Share of U.S. physicians in network: “The company's network members include more than 85% of U.S. physicians across all specialties and practice areas.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ1 FY2027vs year agovs last quarter
Revenue$156.6M+7.3%+7.7%
Operating income$33.6M−38.3%+35.5%
Net income$24.3M−54.4%+27.2%
Diluted EPS$0.13−51.9%—
Free cash flow$41.9M−32.5%—
Gross margin84.9%−4.3 pts−1.8 pts
Operating margin21.5%−15.9 pts+4.4 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Revenuefiscal second quarter ending September 30, 2026between $170 million and $171 million
Adjusted EBITDAfiscal second quarter ending September 30, 2026between $80.5 million and $81.5 million
Revenuefiscal year ending March 31, 2027between $671 million and $681 million
Adjusted EBITDAfiscal year ending March 31, 2027between $309 million and $329 million

Key takeaways

  1. Ask tops U.S.-based models on NOHARM benchmark

    Doximity says its clinical AI assistant, Ask, was the top-performing U.S.-based model in the NOHARM benchmark. Independent safety-style validation supports trust with clinicians and buyers.

  2. Workflow active prescribers grew more than 30%

    Workflow active prescriber growth exceeded 30% year-over-year. The metric counts providers using tools such as Dialer, fax, Ask, PeerCheck, Amion and Scribe, so it shows adoption beyond the core network.

  3. AI Search queries up over 25% sequentially

    AI Search query growth was over 25% quarter-over-quarter. Rapid usage growth gives Doximity a high-intent audience for new AI products and for pharma customers.

  4. AI Search is opening innovation and pharma budgets

    Management says AI Search is starting to win innovation budget, and that pharma has been a surprise source of added market opportunity. It is entering with a lower-cost offering than what customers may have used before.

  5. AI investment is weighing on margins

    R&D, sales and marketing, and cost of revenue all rose faster than revenue, and stock-based compensation climbed. Net income margin fell to 15.5% from 36.5%, so the cost of building clinical AI is itself part of the story.

Charts

Revenue$156.6M+7.3% y/yQ1 FY27
Q3 FY25: $168.6MQ3 25$168.6MQ4 FY25: $138.3M (worked out from the annual figure)Q4 25$138.3MQ1 FY26: $145.9MQ1 26$145.9MQ2 FY26: $168.5MQ2 26$168.5MQ3 FY26: $185.1MQ3 26$185.1MQ4 FY26: $145.4M (worked out from the annual figure)Q4 26$145.4MQ1 FY27: $156.6MQ1 27$156.6MQ2 FY27: $174.5MQ2 27$174.5M

Fourth quarter worked out from the annual figure.

Data
Q3 FY25$168.6M
Q4 FY25$138.3M *
Q1 FY26$145.9M
Q2 FY26$168.5M
Q3 FY26$185.1M
Q4 FY26$145.4M *
Q1 FY27$156.6M
Q2 FY27$174.5M
Diluted EPS (GAAP)$0.13−51.9% y/yQ1 FY27
Q3 FY25: $0.37Q3 25$0.37Q1 FY26: $0.27Q1 26$0.27Q2 FY26: $0.31Q2 26$0.31Q3 FY26: $0.31Q3 26$0.31Q1 FY27: $0.13Q1 27$0.13Q2 FY27: $0.18Q2 27$0.18
Data
Q3 FY25$0.37
Q1 FY26$0.27
Q2 FY26$0.31
Q3 FY26$0.31
Q1 FY27$0.13
Q2 FY27$0.18

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin21.5%−15.9 pts y/yQ1 FY27
Q3 FY25: 47.4%Q3 2547.4%Q4 FY25: 35.2%Q4 2535.2%Q1 FY26: 37.4%Q1 2637.4%Q2 FY26: 37.8%Q2 2637.8%Q3 FY26: 38.9%Q3 2638.9%Q4 FY26: 17.1%Q4 2617.1%Q1 FY27: 21.5%Q1 2721.5%Q2 FY27: 25.2%Q2 2725.2%
Data
Q3 FY2547.4%
Q4 FY2535.2%
Q1 FY2637.4%
Q2 FY2637.8%
Q3 FY2638.9%
Q4 FY2617.1%
Q1 FY2721.5%
Q2 FY2725.2%
Free cash flow$41.9M−32.5% y/yQ1 FY27
Q3 FY25: $65.2MQ3 25$65.2MQ4 FY25: $98.5MQ4 25$98.5MQ1 FY26: $62.1MQ1 26$62.1MQ2 FY26: $93.9MQ2 26$93.9MQ1 FY27: $41.9MQ1 27$41.9MQ2 FY27: $93.3MQ2 27$93.3M
Data
Q3 FY25$65.2M
Q4 FY25$98.5M
Q1 FY26$62.1M
Q2 FY26$93.9M
Q1 FY27$41.9M
Q2 FY27$93.3M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What was Doximity's main product highlight this quarter?

Its clinical AI assistant, Ask, was the top-performing U.S.-based model in the NOHARM benchmark. Management paired this with record engagement.

How is customer and clinician usage trending?

Workflow active prescriber growth was more than 30% year-over-year, and AI Search query growth was over 25% quarter-over-quarter. Doximity's network includes more than 85% of U.S. physicians.

Where is new demand for Doximity's AI products coming from?

Management says AI Search is starting to win innovation budget at health systems, and that pharma has been an unexpected opportunity. It is pitching pharma a lower-cost offering than customers may have used before.

Who does Doximity compete with in AI?

In the ambient scribe market, management names Microsoft as the leader. Doximity competes with Scribe, its HIPAA-compliant ambient note-taking tool, and with Ask, its clinical AI assistant.

What is the tradeoff in Doximity's AI strategy?

Management says it can still post strong software margins while investing heavily in clinical AI. Even so, R&D and cost of revenue rose faster than revenue, and margins fell from a year ago.

Documents

From Doximity investor relations

SEC filing